PURPOSE: Compare the efficacy and safety of two different GnRHa, used for pituitary suppression in IVF cycles. METHODS: A total of 292 patients usingdepot goserelin (Group 1) and 167 using daily leuprolide acetate (Group 2) were compared. Days required to achieve pituitary function suppression, duration of ovarian stimulation, total dose of HMG, number of aspirated follicles, number of oocytes retrieved, and presence of functional ovarian cyst were analyzed. RESULTS: The time taken to achieve downregulation was similar. The mean number of ampoules used for superovulation was higher in Group 1; however, this difference was observed only for patients >40 years old that started GnRHa in the follicular phase. There was no difference between the two groups in the duration of superovulation, in the number of follicles aspirated, and the number of oocytes retrieved. In the group of patients with >40 years the incidence of ovarian cysts was higher in Group 2. CONCLUSIONS: Both routes of GnRHa have similar effects for pituitary suppression and ovulation induction in assisted reproductive technology. Therefore the long-acting GnRHa is an excellent option, as only a single subcutaneous dose is necessary, decreasing the risk of the patient to forget its use and, most important, it does not interfere in the patient's quality of life.
RCT Entities:
PURPOSE: Compare the efficacy and safety of two different GnRHa, used for pituitary suppression in IVF cycles. METHODS: A total of 292 patients using depot goserelin (Group 1) and 167 using daily leuprolide acetate (Group 2) were compared. Days required to achieve pituitary function suppression, duration of ovarian stimulation, total dose of HMG, number of aspirated follicles, number of oocytes retrieved, and presence of functional ovarian cyst were analyzed. RESULTS: The time taken to achieve downregulation was similar. The mean number of ampoules used for superovulation was higher in Group 1; however, this difference was observed only for patients >40 years old that started GnRHa in the follicular phase. There was no difference between the two groups in the duration of superovulation, in the number of follicles aspirated, and the number of oocytes retrieved. In the group of patients with >40 years the incidence of ovarian cysts was higher in Group 2. CONCLUSIONS: Both routes of GnRHa have similar effects for pituitary suppression and ovulation induction in assisted reproductive technology. Therefore the long-acting GnRHa is an excellent option, as only a single subcutaneous dose is necessary, decreasing the risk of the patient to forget its use and, most important, it does not interfere in the patient's quality of life.
Authors: S L Tan; C Kingsland; S Campbell; C Mills; J Bradfield; N Alexander; J Yovich; H S Jacobs Journal: Fertil Steril Date: 1992-04 Impact factor: 7.329
Authors: Luiz Eduardo T Albuquerque; Leopoldo O Tso; Humberto Saconato; Maria Cecília R M Albuquerque; Cristiane R Macedo Journal: Cochrane Database Syst Rev Date: 2013-01-31
Authors: Kang Woo Cheon; Sang Jin Song; Bum Chae Choi; Seung Chul Lee; Hong Bok Lee; Seung Youn Yu; Keun Jai Yoo Journal: J Korean Med Sci Date: 2008-08 Impact factor: 2.153